CCDC63

Across TCGA pan-cancer cohorts, CCDC63 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated CCDC63 data layer compared with 9 for mutation status.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CCDC63 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC63 expression acts as an unfavorable survival marker, although some lineages such as UCS and LIHC show a favorable association.

BLCA, KIRC, and UCS are the cancer types where CCDC63 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Quartile	All	0.283	0.369	.006	34	view →
KIRC	OS	Quartile	All	0.476	0.669	<.001	32	view →
UCS	DFS	Median	II,III,IV	0.553	0.158	.004	30	view →
LGG	DFS	Median	All	0.254	0.521	<.001	27	view →
STAD	OS	Median	II,III,IV	0.229	0.504	.008	25	view →
LIHC	OS	Tertile	III,IV	1.000	0.618	.005	22	view →
LUSC	DFS	Quartile	II,III,IV	0.465	0.690	.002	20	view →
THCA	OS	Tertile	IV	0.582	0.897	.008	15	view →
MESO	OS	Median	II,III,IV	0.347	0.698	.024	15	view →
CESC	OS	Median	II,III,IV	0.640	0.444	.031	12	view →
ESCA	DFS	Median	All	0.428	0.587	.014	10	view →
GBM	OS	Quartile	All	0.455	0.276	.023	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

CCDC63–BLCA (DFS)

Open the BLCA breakdown →